Receive monthly emails about the latest oncology research and technology, new patient services, resources and more!

Please select an option below to help us tailor your newsletter to best suit your content interests!

No thanks

Axel Grothey, MD, medical oncologist and director of Gastrointestinal Cancer Research at West Cancer Center and Research Institute, discusses the potential utility of trifluridine/tipiracil (TAS-102; Lonsurf) in combination with bevacizumab (Avastin) in metastatic colorectal cancer (mCRC).

Currently, TAS-102 is reserved for single-agent use in the third-line setting for patients with mCRC, says Grothey. However, TAS-102 in combination with bevacizumab has reported clinical benefit for patients with mCRC in 2 randomized studies, Grothey explains.

Data from a randomized phase 2 Danish study (EudraCT, 2016-005241-23) demonstrated an improvement in progression-free survival and a tolerable safety profile with TAS-102 plus bevacizumab compared with TAS-102 alone in patients with mCRC who were refractory to chemotherapy.

Additionally, findings from the final analysis of the phase 2 TASCO1 trial, which were presented during the 2021 Gastrointestinal Cancers Symposium, revealed an improvement in overall survival with TAS-102 plus bevacizumab vs capecitabine plus bevacizumab when used as frontline therapy for patients with unresectable mCRC who are not eligible for standard chemotherapy, concludes Grothey.

 

https://www.onclive.com/view/dr-grothey-on-the-potential-utility-of-tas-102-bevacizumab-in-metastatic-crc?fbclid=IwAR3Sg_vi9B8hefMq7aITwddxgmI-8VBGVK-QF0-lgioLhX4Kfn8s-lWC1C8

X